Here is a summary of the content in 400 words:
Glenmark Pharmaceuticals, USA has launched Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial). This product is bioequivalent and therapeutically equivalent to the reference listed drug, Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial of Mylan Laboratories Limited.
The market for Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial) has achieved annual sales of approximately $39.3 million, according to IQVIA sales data for the 12-month period ending January 2025.
Marc Kikuchi, President & Business Head, North America at Glenmark, commented on the launch, saying, “We are excited to announce the launch of Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial), adding another quality product to our institutional portfolio.”
This launch further solidifies Glenmark’s position as a prominent player in the pharmaceutical industry, driven by its commitment to providing high-quality and innovative products to patients. At a time when the pharmaceutical industry is witnessing significant changes, Glenmark’s launch of Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial), demonstrates its dedication to delivering quality medication to patients.